دورية أكاديمية
Preoperative hydronephrosis is an independent protective factor of renal function decline after nephroureterectomy for upper tract urothelial carcinoma.
| العنوان: | Preoperative hydronephrosis is an independent protective factor of renal function decline after nephroureterectomy for upper tract urothelial carcinoma. |
|---|---|
| المؤلفون: | Cheng PY; Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.; Divisions of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan., Lee HY; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan., Li WM; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.; Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan.; Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan., Huang SK; Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.; Department of Medical Science Industries, College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan., Liu CL; Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan., Chen IA; Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan., Lin JT; Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan., Lo CW; Division of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan., Yu CC; Division of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan.; School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan., Wang SS; Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.; Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan., Chen CS; Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.; Department of Senior Citizen Service Management, National Taichung University of Science and Technology, Taichung, Taiwan., Tseng JS; Department of Urology, MacKay Memorial Hospital, Taipei, Taiwan.; Mackay Medical College, Taipei, Taiwan.; Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan., Lin WR; Department of Urology, MacKay Memorial Hospital, Taipei, Taiwan.; Mackay Medical College, Taipei, Taiwan., Yeong-Chin J; Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.; Department of Health and Nutrition Biotechnology, Asian University, Taichung, Taiwan., Cheong IS; Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan., Jiang YH; Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan., Lee YK; Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan., Chen YT; Department of Urology Taiwan Adventist Hospital, Taipei, Taiwan., Chen SH; Department of Urology Taiwan Adventist Hospital, Taipei, Taiwan., Chiang BJ; College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.; Department of Urology, Cardinal Tien Hospital, New Taipei City, Taiwan.; Department of Life Science, College of Science, National Taiwan Normal University, Taipei, Taiwan., Hsueh TY; Division of Urology, Department of Surgery, Taipei City Hospital renai branch, Taipei, Taiwan.; Department of Urology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan., Huang CY; Department of Urology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan., Wu CC; Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei, Taiwan., Lin WY; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi, Taiwan.; Chang Gung University of Science and Technology, Chia-Yi, Taiwan.; Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan., Tsai YC; School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan.; Department of Surgery, Taipei Tzu chi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.; Department of Urology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan., Yu KJ; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.; School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Department of Chemical Engineering and Biotechnology and Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei, Taiwan., Huang CP; Department of Urology, China Medical University and Hospital, Taichung, Taiwan.; School of Medicine, China Medical University, Taichung, Taiwan., Huang YY; Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan., Tsai CY; Divisions of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan.; Department of Electrical Engineering, Yuan Ze University, Taoyuan, Taiwan. |
| المصدر: | Frontiers in oncology [Front Oncol] 2023 Feb 24; Vol. 13, pp. 944321. Date of Electronic Publication: 2023 Feb 24 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Objectives: To evaluate the predictive role of pre-nephroureterectomy (NU) hydronephrosis on post-NU renal function (RF) change and preserved eligibility rate for adjuvant therapy in patients with upper tract urothelial carcinoma (UTUC). Patients and Methods: This retrospective study collected data of 1018 patients from the Taiwan UTUC Collaboration Group registry of 26 institutions. The patients were divided into two groups based on the absence or presence of pre-NU hydronephrosis. Estimated glomerular filtration rate (eGFR) was calculated pre- and post-NU respectively. The one month post-NU RF change, chronic kidney disease (CKD) progression, and the preserved eligibility rate for adjuvant therapy were compared for each CKD stage. Results: 404 (39.2%) patients without and 614 (60.8%) patients with pre-NU hydronephrosis were enrolled. The median post-NU change in the eGFR was significantly lower in the hydronephrosis group (-3.84 versus -12.88, p<0.001). Pre-NU hydronephrosis was associated with a lower post-NU CKD progression rate (33.1% versus 50.7%, p < 0.001) and was an independent protective factor for RF decline after covariate adjustment (OR=0.46, p <0.001). Patients with pre-NU hydronephrosis had a higher preserved eligibility rate for either adjuvant cisplatin-based chemotherapy (OR=3.09, 95%CI 1.95-4.69) or immune-oncology therapy (OR=2.31, 95%CI 1.23-4.34). Conclusion: Pre-NU hydronephrosis is an independent protective predictor for post-NU RF decline, CKD progression, and eligibility for adjuvant therapy. With cautious selection for those unfavorably prognostic, non-metastatic UTUC patients with preoperative hydronephrosis, adjuvant rather than neoadjuvant therapy could be considered due to higher chance of preserving eligibility. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Cheng, Lee, Li, Huang, Liu, Chen, Lin, Lo, Yu, Wang, Chen, Tseng, Lin, Yeong-Chin, Cheong, Jiang, Lee, Chen, Chen, Chiang, Hsueh, Huang, Wu, Lin, Tsai, Yu, Huang, Huang and Tsai.) |
| References: | Eur Urol. 2014 Sep;66(3):529-41. (PMID: 24680361) Int J Clin Oncol. 2020 Jun;25(6):1037-1054. (PMID: 32206939) Urology. 2016 Oct;96:44-53. (PMID: 27443467) Eur Urol. 2016 Dec;70(6):1052-1068. (PMID: 27477528) Can J Urol. 2016 Aug;23(4):8334-41. (PMID: 27544555) Medicine (Baltimore). 2016 Jul;95(30):e4203. (PMID: 27472690) J Physiol. 1972 Jan;220(1):199-210. (PMID: 5059234) Eur J Cancer. 2012 Mar;48(4):456-64. (PMID: 22119351) J Urol. 2018 Jun;199(6):1440-1445. (PMID: 29427584) J Clin Oncol. 2011 Jun 10;29(17):2432-8. (PMID: 21555688) Kidney Int. 2013 Sep;84(3):622-3. (PMID: 23989362) Clin J Am Soc Nephrol. 2016 Jan 7;11(1):101-7. (PMID: 26500248) Hematol Oncol Clin North Am. 2015 Apr;29(2):271-88, ix. (PMID: 25836934) In Vivo. 2020 Sep-Oct;34(5):2431-2435. (PMID: 32871769) J Clin Oncol. 2017 Mar 10;35(8):852-860. (PMID: 28045620) N Engl J Med. 2021 Nov 4;385(19):1737-1749. (PMID: 34554658) Eur Urol. 2010 Oct;58(4):581-7. (PMID: 20619530) Eur Urol. 2018 Dec;74(6):833-839. (PMID: 30224195) CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402) Ann Intern Med. 2006 Aug 15;145(4):247-54. (PMID: 16908915) Cancer. 2010 Jun 15;116(12):2967-73. (PMID: 20564402) Eur Urol. 2014 Aug;66(2):181-3. (PMID: 24361259) Eur Urol. 2021 May;79(5):635-654. (PMID: 32798146) BJU Int. 2014 Mar;113(3):408-15. (PMID: 23937424) Curr Urol Rep. 2013 Apr;14(2):94-101. (PMID: 23344684) Lancet Oncol. 2006 Sep;7(9):735-40. (PMID: 16945768) Lancet. 2020 Apr 18;395(10232):1268-1277. (PMID: 32145825) Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839) J Surg Oncol. 2014 Sep;110(4):468-75. (PMID: 25059848) Nat Rev Urol. 2015 Mar;12(3):155-66. (PMID: 25708579) PLoS One. 2014 Jun 13;9(6):e99645. (PMID: 24927124) N Engl J Med. 2021 Jun 3;384(22):2102-2114. (PMID: 34077643) Urol Oncol. 2014 Jan;32(1):31.e17-24. (PMID: 23428535) Front Oncol. 2022 Jan 13;11:766576. (PMID: 35096575) BJU Int. 2014 Nov;114(5):674-9. (PMID: 24314050) Eur Urol Oncol. 2018 May;1(1):54-60. (PMID: 30420974) Jpn J Clin Oncol. 2012 Mar;42(3):202-7. (PMID: 22246718) |
| فهرسة مساهمة: | Keywords: adjuvant therapy; chronic kidney disease; cisplatin-based chemotherapy; hydronephrosis; immune-oncology therapy; nephroureterectomy; renal function; upper tract urothelial carcinoma |
| تواريخ الأحداث: | Date Created: 20230313 Latest Revision: 20230314 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9998910 |
| DOI: | 10.3389/fonc.2023.944321 |
| PMID: | 36910617 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2023.944321 |